Difference between revisions of "Epratuzumab (LymphoCide)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Intravenous chemotherapy" to "Category:Intravenous medications") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Acute lymphocytic leukemia medications" to "Category:B-cell acute lymphoblastic leukemia medications") |
||
| Line 14: | Line 14: | ||
[[Category:Anti-CD22 antibodies]] | [[Category:Anti-CD22 antibodies]] | ||
| − | [[Category: | + | [[Category:B-cell acute lymphoblastic leukemia medications]] |
[[Category:Investigational]] | [[Category:Investigational]] | ||
Revision as of 20:37, 22 January 2018
Mechanism of action
Anti-CD22 antibody
Preliminary data
Acute lymphocytic leukemia
- Advani AS, McDonough S, Coutre S, Wood B, Radich J, Mims M, O'Donnell M, Elkins S, Becker M, Othus M, Appelbaum FR. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 May;165(4):504-9. Epub 2014 Mar 3. PubMed link to original article